Pharma technology is experiencing a significant resurgence, with investors and entrepreneurs reporting unprecedented alignment around artificial intelligence (AI) and enterprise demand. According to a new report from McKesson Ventures, which surveyed more than 100 industry participants including 54 investors and 49 entrepreneurs, momentum is accelerating across the sector as AI creates new opportunities to modernize complex pharmaceutical workflows.

Why Are Investors Suddenly Bullish on Pharma Tech?

The shift in investor sentiment is striking. A significant majority of investors report increased interest in pharma tech compared with other healthcare sectors, driven by the belief that pharmaceutical companies have greater appetite for AI adoption and more opportunities to replace outdated legacy systems. This represents a meaningful change in how venture capital views the pharmaceutical technology space.

The survey identified several areas attracting the most investment attention across the drug development lifecycle:

• Clinical Trial Design: AI-powered tools that help design and simulate clinical trials more efficiently
• Trial Operations: Software that streamlines the execution and management of ongoing clinical studies
• Patient Support Services: Technology platforms that improve patient engagement and adherence to treatment protocols
• Healthcare Provider Engagement: Tools that help pharmaceutical companies connect with doctors and medical professionals
• Drug Discovery Tools: AI systems that accelerate the identification and development of new drug candidates

What's Changed for Entrepreneurs Selling Pharma Tech?

The sales environment has transformed dramatically for startup founders building pharmaceutical technology solutions. Nearly half of entrepreneurs report that selling has become easier, citing stronger executive sponsorship from pharmaceutical companies, growing urgency around AI implementation, faster movement from pilot programs to full production deployment, and greater ability to demonstrate return on investment. This represents a fundamental shift in how pharmaceutical companies evaluate and adopt new technology.

"It's exciting to see more alignment across the pharma tech ecosystem. Investors are increasingly optimistic, entrepreneurs are finding greater buyer receptivity, and AI is creating new opportunities to modernize some of the industry's most complex workflows. The companies that win will be those solving large, meaningful problems that pharma companies cannot easily address on their own," said Michelle Snyder, Partner at McKesson Ventures.

Michelle Snyder, Partner at McKesson Ventures

How Are Pharma Companies Changing Their Pricing Models?

One of the most significant shifts involves how pharmaceutical companies pay for technology. Three-quarters of companies report changing their pricing strategy since launch, with growing adoption of usage-based and outcomes-based pricing approaches. This reflects a broader trend where pharma buyers seek tighter alignment between the cost of technology and the actual value it delivers to their business.

Usage-based pricing means companies pay based on how much they actually use a tool, while outcomes-based pricing ties costs directly to measurable results, such as faster drug approval or reduced clinical trial costs. This shift suggests pharmaceutical companies are becoming more sophisticated buyers who want to tie technology investments directly to business outcomes.

Where Is the Disconnect Between Investors and Entrepreneurs?

Despite the overall optimism, the survey revealed some divergence in how investors and entrepreneurs view the market. Entrepreneurs report relatively less investor interest and lower conviction around budget availability and sales cycle improvements compared with what investors themselves report. This gap suggests that while the overall market sentiment is positive, individual entrepreneurs may still face challenges securing funding or closing deals, even as the sector overall experiences momentum.

The survey data indicates that AI has become the primary driver of market momentum for both investors and entrepreneurs. Both groups cite increased interest in AI as a leading force behind customer adoption and investment activity, suggesting that pharmaceutical companies view AI not as a nice-to-have feature but as essential infrastructure for modernizing their operations and accelerating drug development timelines.

As pharmaceutical companies continue to seek ways to improve productivity and accelerate development timelines, the convergence of investor confidence, entrepreneur optimism, and enterprise demand for AI-powered solutions appears to be creating a genuine inflection point in how the industry approaches technology innovation across research, clinical development, and commercialization functions.